-
乳腺癌的发病率逐年上升,WHO国际癌症研究机构2018年统计数据表明,2018年全球被诊断为乳腺癌的患者达200多万例,超过60万例女性患者病死于乳腺癌,且乳腺癌在女性中的发病率(24.2%)和病死率(15%)均较高[1]。乳腺癌的高病死率大多是由于肿瘤远处转移,但由于乳腺癌的高度异质性,其转移机制尚不明确。
目前临床上对乳腺癌分型主要依靠有创的组织病理学检查,而且大多是发现乳腺肿物并行手术治疗后才可以进行,不适用于乳腺癌的早期筛查及分子分型。分子影像学技术通过采用不同的分子探针,特异性地标记人体内的蛋白质、受体或基因等,可以从疾病早期血流灌注、代谢及受体水平变化等方面对疾病作出早期诊断。SPECT/CT是一种可以用于乳腺癌分子影像学诊断的有效方法。分子影像探针的选择需要结合肿瘤的特性,因此,基于乳腺肿瘤内新生血管丰富的特性可以选择适用于乳腺癌分子影像的分子探针。
99Tcm-3PRGD2 SPECT/CT分子影像在乳腺癌诊疗中的应用进展
Progress of 99Tcm-3PRGD2 SPECT/CT molecular imaging in the diagnosis and treatment of breast cancer
-
摘要: 乳腺癌是女性发病率最高的恶性肿瘤。99Tcm-联胼尼克酰胺-3聚乙二醇-精氨酸-甘氨酸-天冬氨酸环肽二聚体(99Tcm-3PRGD2)是近年来人工合成的可用于乳腺癌分子显像的一种SPECT示踪剂。99Tcm-3PRGD2 SPECT/CT可用于早期诊断乳腺癌并进行准确的分期及分子分型,据此进行诊疗方案的选择,有助于降低患者的病死率,并提高患者的生活质量。笔者就99Tcm-3PRGD2 SPECT/CT在乳腺癌诊疗过程中的应用进展进行综述,并作出展望。
-
关键词:
- 乳腺肿瘤 /
- 体层摄影术,发射型计算机,单光子 /
- 整合素αVβ3 /
- 体层摄影术,X线计算机 /
- RGD序列
Abstract: Breast cancer is the most common malignant tumor in women. 99Tcm-hydrazino-nicotinamide(HYNIC)-(poly-(ethylene glycol), PEG)4-Glu (cyclo(Arg-Gly-Asp-D-Phe-Lys(PEG4)))2 (99Tcm-3PRGD2) is a kind of artificial synthesized molecular tracer, which can be used to SPECT/CT for breast cancer imaging. 99Tcm-3PRGD2 SPECT/CT can be used for early diagnosis, accurate staging and molecular typing of the breast cancer. Selecting the treatment regimen according to the result of 99Tcm-3PRGD2 SPECT/CT is helpful to reduce the mortality of patients and improve the quality of life of patients. The application progress of 99Tcm-3PRGD2 SPECT/CT in the diagnosis of breast cancer is reviewed and prospected in this paper. -
[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394−424. DOI: 10.3322/caac.21492. [2] Folkman J. Tumor angiogenesis: therapeutic implications[J]. N Engl J Med, 1971, 285(21): 1182−1186. DOI: 10.1056/nejm197111182852108. [3] Miladinova D. Molecular imaging in breast cancer[J]. Nucl Med Mol Imaging, 2019, 53(5): 313−319. DOI: 10.1007/s13139-019-00614-w. [4] 刁利梅, 熊小明, 杨成万, 等. 整合素ανβ3、ERK1/2在宫颈鳞癌中的表达及其与血管生成拟态的关系[J]. 现代医药卫生, 2017, 33(3): 343−346. DOI: 10.3969/j.issn.1009-5519.2017.03.009.
Diao LM, Xiong XM, Yang CW, et al. Expression of αvβ3 integrin and ERK1/2 in cervical squamous cell carcinoma and its relation with vasculogenic mimicry[J]. J Mod Med, 2017, 33(3): 343−346. DOI: 10.3969/j.issn.1009-5519.2017.03.009.[5] 张新超, 边艳珠, 国方娜, 等. 99Tcm-3PRGD2 SPECT诊断大鼠骨移植瘤[J]. 中国医学影像技术, 2020, 36(2): 206−209. DOI: 10.13929/j.issn.1003-3289.2020.02.009.
Zhang XC, Bian YZ, Guo FN, et al. 99Tcm-3PRGD2 SPECT in diagnosis of rat bone graft tumors[J]. Chin J Med Imag Technol, 2020, 36(2): 206−209. DOI: 10.13929/j.issn.1003-3289.2020.02.009.[6] Chakravarty R, Chakraborty S, Dash A. Molecular imaging of breast cancer: role of RGD peptides[J]. Mini Rev Med Chem, 2015, 15(13): 1073−1094. DOI: 10.2174/1389557515666150909144606. [7] Janssen ML, Oyen WJ, Dijkgraaf I, et al. Tumor targeting with radiolabeled αvβ3 integrin binding peptides in a nude mouse model[J]. Cancer Res, 2002, 62(21): 6146−6151. [8] 李万婷. 99mTc-3PRGD2 SPECT/CT鉴别诊断乳腺良恶性及与分子分型关系的研究[D]. 太原: 山西医科大学, 2018.
Li WT. The value of 99mTc-3PRGD2 SPECT/CT of identify benign and malignant breast lesions and the relationship with molecular subtype[D]. Taiyuan: Shanxi Medical University, 2018.[9] 王健, 宋秀宇, 徐文贵, 等. 乳腺癌放射性核素分子成像研究进展[J]. 国际医学放射学杂志, 2015, 38(4): 361−365. DOI: 10.3874/j.issn.1674-1897.2015.04.Z0411.
Wang J, Song XY, Xu WG, et al. The research progress of radionuclide molecular imaging for breast cancer[J]. Int J Radiat Med Nucl Med, 2015, 38(4): 361−365. DOI: 10.3874/j.issn.1674-1897.2015.04.Z0411.[10] Ortiz-Arzate Z, Santos-Cuevas CL, Ocampo-García BE, et al. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging[J]. Nucl Med Commun, 2014, 35(4): 423−432. DOI: 10.1097/mnm.0000000000000065. [11] Chen ZY, Fu FM, Li F, et al. Comparison of [99mTc]3PRGD2 imaging and [18F]FDG PET/CT in breast cancer and expression of integrin αvβ3 in breast cancer vascular endothelial cells[J]. Mol Imaging Biol, 2018, 20(5): 846−856. DOI: 10.1007/s11307-018-1178-y. [12] 高大鹏. 99mTc-3P4-RGD2与99mTc-MIBI SPECT显像诊断乳腺癌的价值的对比研究[D]. 长春: 吉林大学, 2015.
Gao DP. 99mTc-3P4-RGD2 scintimammography in the assessment of breast lesions: comparative study with 99mTc-MIBI[D]. Changchun: Jilin University, 2015.[13] 马庆杰, 陈滨, 高识, 等. 99Tcm-3P4-RGD2与99Tcm-MIBI SPECT显像诊断乳腺癌的对比研究[J]. 中华核医学与分子影像杂志, 2016, 36(2): 184−185. DOI: 10.3760/cma.j.issn.2095-2848.2016.02.019.
Ma QJ, Chen B, Gao S, et al. 99Tcm-3P4-RGD2 scintimammography in the assessment of breast lesions: comparative study with 99Tcm-MIBI[J]. Chin J Nucl Med Mol Imaging, 2016, 36(2): 184−185. DOI: 10.3760/cma.j.issn.2095-2848.2016.02.019.[14] Zhao ZQ, Yang Y, Fang W, et al. Comparison of biological properties of 99mTc-labeled cyclic RGD peptide trimer and dimer useful as SPECT radiotracers for tumor imaging[J]. Nucl Med Biol, 2016, 43(11): 661−669. DOI: 10.1016/j.nucmedbio.2016.02.006. [15] Wang LJ, Shi JY, Kim YS, et al. Improving tumor-targeting capability and pharmacokinetics of 99mTc-labeled cyclic RGD dimers with PEG4 linkers[J]. Mol Pharm, 2009, 6(1): 231−245. DOI: 10.1021/mp800150r. [16] Liu L, Song Y, Gao S, et al. 99mTc-3PRGD2 scintimammography in palpable and nonpalpable breast lesions[J]. Mol Imaging, 2014, 13(5). DOI: 10.2310/7290.2014.00010. [17] 王任婕. 99mTc-3PRGD2 SPECT/CT显像在乳腺癌中的应用[D]. 长春: 吉林大学, 2013.
Wang RJ. The application of 99mTc-3PRGD2 SPECT/CT imaging in the patients of breast cancer[D]. Changchun: Jilin University, 2013.[18] 梁宏伟. 99Tcm-3PRGD2单光子发射计算机断层显像/CT在乳腺癌诊断中应用评价[J]. 中国药物与临床, 2020, 20(22): 3728−3731. DOI: 10.11655/zgywylc2020.22.005.
Liang HW. Value of 99Tcm-3PRGD2 SPECT/CT in diagnosing breast cancer[J]. Chinese Remedies Clinics, 2020, 20(22): 3728−3731. DOI: 10.11655/zgywylc2020.22.005.[19] 丁森. 99mTc-3PRGD2 SPECT/CT显像评估乳腺病变的临床价值: 对比超声[D]. 苏州: 苏州大学, 2018.
Ding S. The clinical role of 99mTc-3PRGD2 SPECT/CT in the diagnosis of breast cancer: a comparison with ultrasound[D]. Suzhou: Soochow University, 2018.[20] 柳林, 宋研, 高识, 等. 99Tcm-3P4-RGD2 SPECT显像在乳腺癌诊断中的应用价值[J]. 中华核医学与分子影像杂志, 2015, 35(6): 498−499. DOI: 10.3760/cma.j.issn.2095-2848.2015.06.018.
Liu L, Song Y, Gao S, et al. 99mTc-3PRGD2 scintimammography in palpable and nonpalpable breast lesions[J]. Chin J Nucl Med Mol Imaging, 2015, 35(6): 498−499. DOI: 10.3760/cma.j.issn.2095-2848.2015.06.018.[21] Chen GB, Ouyang Z, Wang F, et al. Evaluation of Tc-99m-3PRGD2 integrin receptor imaging in the differential diagnosis of breast lesions and comparison with mammography[J]. Cancer Invest, 2017, 35(2): 108−115. DOI: 10.1080/07357907.2016.1270957. [22] 李万婷, 刘海燕, 秦丽军, 等. 99Tcm-3PRGD2整合素受体显像鉴别乳腺良恶性病变的价值及与超声检查的对比研究[J]. 国际放射医学核医学杂志, 2018, 42(3): 242−247. DOI: 10.3760/cma.j.issn.1673-4114.2018.03.009.
Li WT, Liu HY, Qin LJ, et al. The evaluation of 99Tcm-3PRGD2 integrin receptor imaging in the differential diagnosis in benign and malignant breast lesions comparision with ultrasound[J]. Int J Radiat Med Nucl Med, 2018, 42(3): 242−247. DOI: 10.3760/cma.j.issn.1673-4114.2018.03.009.[23] Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017[J]. Ann Oncol, 2017, 28(8): 1700−1712. DOI: 10.1093/annonc/mdx308. [24] 刘海燕, 李万婷, 秦丽军, 等. 99Tcm-3PRGD2 SPECT/CT显像半定量参数与乳腺癌临床病理特征的关系[J]. 中华核医学与分子影像杂志, 2018, 38(12): 786−789. DOI: 10.3760/cma.j.issn.2095-2848.2018.12.003.
Liu HY, Li WT, Qin LJ, et al. Relationship between the semi-quantitative index of 99Tcm-3PRGD2 SPECT/CT imaging and clinical pathological features of breast cancer[J]. Chin J Nucl Med Mol Imaging, 2018, 38(12): 786−789. DOI: 10.3760/cma.j.issn.2095-2848.2018.12.003.[25] 欧阳忠, 陈贵兵. 99mTc-3PRGD2 SPECT/CT显像在乳腺癌分子分型中的应用研究[J]. 中国卫生标准管理, 2018, 9(18): 124−126. DOI: 10.3969/j.issn.1674-9316.2018.18.055.
Ouyang Z, Chen GB. Study on the application of 99mTc-3PRGD2 SPECT/CT imaging in the molecular typing of breast cancer[J]. Chin Heal Standard Management, 2018, 9(18): 124−126. DOI: 10.3969/j.issn.1674-9316.2018.18.055.[26] 闵楷茵. 乳腺癌显像药物99mTc-AF7P动物显像和99mTc-3PRGD2临床应用的研究[D]. 长春: 吉林大学, 2017.
Min KY. Researches on 99mTc-labelled polypeptide receptor imaging by AF7P in animal models and 3PRGD2 in patients with breast cancer[D]. Changchun: Jilin University, 2017.[27] Zhou Y, Shao GQ, Liu S. Monitoring breast tumor lung metastasis by U-SPECT-II/CT with an integrin αvβ3-targeted radiotracer 99mTc-3P-RGD2[J/OL]. Theranostics, 2012, 2(6): 577−588[2020-12-27]. https://www.thno.org/v02p0577.htm. DOI: 10.7150/thno.4443. [28] 邵国强. 99mTc-3P-RGD2显像定量评价肿瘤整合素αvβ3表达及其应用的实验研究[D]. 南京: 南京医科大学, 2012.
Shao GQ. The study on the quantitive analysis of tumor integrin αvβ3 expression level by U-SPECT-CT imaging with integrin αvβ3 targeting radiotracer 99mTc-3P-RGD2 and its potent application value[D]. Nanjing: Nanjing Medical University, 2012.[29] 陈珍英. 99mTc-3PRGD2 SPECT显像对乳腺癌及腋窝淋巴结转移的诊断价值[D]. 福州: 福建医科大学, 2016.
Chen ZY. Diagnostic value of 99mTc-3PRGD2 SPECT imaging for breast cancer and axillary lymph node metastasis[D]. Fuzhou: Fujian Medical University, 2016.[30] Ji SD, Zheng YM, Shao G, et al. Integrin αvβ3-targeted radiotracer 99mTc-3P-RGD2 useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin αvβ3 RGD2 therapy[J/OL]. Theranostics, 2013, 3(11): 816−830[2020-12-27]. https://www.thno.org/v03p0816.htm. DOI: 10.7150/thno.6989. [31] Ji B, Chen B, Wang T, et al. 99mTc-3PRGD2 SPECT to monitor early response to neoadjuvant chemotherapy in stage Ⅱ and Ⅲ breast cancer[J]. Eur J Nucl Med Mol Imaging, 2015, 42(9): 1362−1370. DOI: 10.1007/s00259-015-3062-1. [32] Chen QQ, Xie Q, Zhao M, et al. Diagnostic value of 99mTc-3PRGD2 scintimammography for differentiation of malignant from benign breast lesions: comparison of visual and semi-quantitative analysis[J]. Hell J Nucl Med, 2015, 18(3): 193−198. DOI: 10.1967/s002449910302. [33] Dorbala S, Kijewski MF, Park MA. Quantitative bone-avid tracer SPECT/CT for cardiac amyloidosis: a crucial step forward[J]. JACC: Cardiovasc Imaging, 2020, 13(6): 1364−1367. DOI: 10.1016/j.jcmg.2020.05.005.
计量
- 文章访问数: 5591
- HTML全文浏览量: 4475
- PDF下载量: 23